FLT3 and acute myeloid leukemia: As a consequence, the drug activity was also investigated in combination with standard chemotherapy in FLT3-mutated newly-diagnosed AML patients (crenolanib at the dosage of 100 mg, three times/day; chemotherapy according to “3 + 7” schedule), leading to a CR rate with a full count recovery of 96%.